Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines

J Am Coll Cardiol. 2019 Aug 6;74(5):712-714. doi: 10.1016/j.jacc.2019.05.051.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • American Heart Association*
  • Anticholesteremic Agents / therapeutic use*
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy*
  • Biomarkers / blood
  • Cardiology*
  • Cholesterol / blood*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Practice Guidelines as Topic*
  • Risk Assessment*
  • Risk Factors
  • United States

Substances

  • Anticholesteremic Agents
  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cholesterol